Ümmüşen KAYA AKÇA, Okan SÖKMEN, Ertuğrul Çağrı BÖLEK, Selcan DEMİR, Levent KILIÇ, Işın ÜNAL, Yelda BİLGİNER

A case report of intracranial hypertension and aseptic meningitis: anti-tumor necrosis factor associated or juvenile idiopathic arthritis related

Background. The adverse effects of tumor necrosis factor alpha inhibitors (TNFi) are well characterized but rare adverse events are increasing day by day. Case. We presented an 18-year-old girl with rheumatoid factor positive polyarticular juvenile idiopathic arthritis (JIA) who developed fever, headache, and nausea after the second dose of adalimumab. In addition to her suspicious complaints for meningitis, she had bilateral papilledema and partial abducens nerve palsy. Leptomeningeal contrast enhancement was noted in magnetic resonance imaging (MRI) of the brain. Brain MRI venography was normal. The cerebrospinal fluid (CSF) opening pressure was high but CSF analysis was normal. She was diagnosed with non-infectious subacute meningitis. Since brain biopsy was not performed, no definite distinction could be made between TNFi related aseptic meningitis or cerebral involvement of JIA. Due to the onset of neurological complaints after initiation of adalimumab treatment and rare cerebral involvement in JIA, the drug-associated aseptic meningitis was likely to be responsible in our patient. Adalimumab was discontinued and methylprednisolone followed by methotrexate treatment were initiated. Her symptoms resolved and control brain MRI was normal. Conclusion. Pediatric rheumatologists should be aware of this potentially severe side effect of anti-TNF treatment.

PDF

___

1. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534.

2. Arnason B, Jacobs G, Hanlon M, et al; The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS-results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465.

3. Booker MJ, Flint J, Saravana S. Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report. Cases J 2008; 1: 364.

4. Wang DY, Chong WS, Pan JY, Heng YK. First case report of aseptic meningitis induced by adalimumab administered for treatment of chronic plaque psoriasis. J Investig Allergol Clin Immunol 2017; 27: 183-185.

5. Junga Z, Theeler B, Singla M. Infliximab-induced aseptic meningitis in a patient with Crohn’s disease. ACG Case Rep J 2018; 5: e48.

6. Jazeron A, Lallier JC, Rihn B, Thiercelin MC. Aseptic meningitis possibly induced by adalimumab. Joint Bone Spine 2010; 6: 618-619.

7. López Méndez PL, Martín Santana I, del Pino Reyes Yánez M, , Ruano Hernández A, Hernández Beriain JÁ, Hervás García M. Meningeal and Guillain–Barrè syndrome in a patient with rheumatoid arthritis receiving adalimumab therapy. Reumatol Clin 2011; 7: 401-403.

8. Marotte H, Charrin JE, Miossec P. Infliximabinduced aseptic meningitis. Lancet 2001; 358: 1784.

9. Honda Y, Otsuka A, Egawa G, et al. Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-α therapy in psoriatic arthritis. Eur J Dermatol 2015; 25: 487-488.

10. Manthey C, Lohse AW, Pace A. Case report of aseptic meningitis in a patient with Crohn’s disease under infliximab therapy. Inflamm Bowel Dis 2011; 17: E10.

11. Shah R, Shah M, Bansal N, Manocha D. Infliximabinduced aseptic meningitis. Am J Emerg Med 2014; 32: 1560.e3-4.

12. Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry 2018; 89: 1088-1100.

13. Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, et al; Biobadaser Group. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 2008; 26: 854-859.

14. Matsuura-Otsuki Y, Hanafusa T, Yokozeki H, Watanabe K. Infliximab-induced aseptic meningitis during the treatment of psoriatic arthritis. Case Rep Dermatol 2017; 9: 26-29.

15. Mount HR, Boyle SD. Aseptic and bacterial meningitis: evaluation, treatment, and prevention. Am Fam Physician 2017; 96: 314-322.

16. Pashankar D, McArdle M, Robinson A. Cotrimoxazole induced aseptic meningitis. Arch Dis Child 1995; 73: 257-258.

17. Jolles S, Sewell WC, Leighton C. Drug-induced aseptic meningitis. Drug Saf 2000; 22: 215-226.

18. Jan JE, Hill RH, Low MD. Cerebral complications in juvenile rheumatoid arthritis. Can Med Assoc J 1972; 107: 623-625.

19. Bathon JM, Moreland LW, DiBartolomeo AG. Inflammatory central nervous system involvement in rheumatoid arthritis. Semin Arthritis Rheum 1989; 18: 258-266.

20. Huys AML, Guerne PA, Horvath J. Rheumatoid meningitis occurring during adalimumab and methotrexate treatment. Joint Bone Spine 2012; 79: 90-92.

21. Yelehe-Okouma M, Czmil-Garon J, Pape E, Petitpain N, Gillet P. Drug-induced aseptic meningitis: a minireview. Fundam Clin Pharmacol 2018; 32: 252-260.